PureTech Health is cutting a small number of positions after a recent decision to deprioritize work on an early-stage drug delivery technology, a spokesperson for the biotechnology company creator confirmed to BioPharma Dive.
PureTech, which has founded a handful of biotechs in addition to developing its own drugs, will no longer advance its “Orasome” platform, and instead will focus resources elsewhere in its pipeline. Orasome was used by PureTech to refer to technology for the oral delivery of therapeutic payloads like messenger RNA that would typically be delivered by injection.
